Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE)

Examine [NCT00968708]

Description: The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in subjects with type 2 diabetes mellitus and acute coronary syndrome.

Drug: Alogliptin; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Alogliptin (DPP-4 inhibitor) vs placebo
Add on therapy
At least 4.75 year cardiovascular event trial
Patient receives All DM medications free
Daiichi Sankyo